Long-term follow-up after cadonilimab (AK104) treatment
Official title: An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Run by Akeso · NCT07547787 · Data updated 2026-11-12
This follow-up collects long-term health and survival information from people with advanced gastric cancer who previously received cadonilimab (AK104) in earlier clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 610 (estimated) |
| Sponsor | Akeso Industry-sponsored |
| Drugs / interventions | cadonilimab |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | December 26, 2024 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2040 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT07547787 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with locally advanced unresectable or metastatic gastric cancer who previously received cadonilimab (AK104) in a sponsor trial, completed that trial, and can provide informed consent for extended follow-up.
✕Probably not a fit
Patients who did not receive cadonilimab previously, cannot provide informed consent, or who cannot be followed at the study site are unlikely to receive benefit from participation and should not expect direct therapeutic benefit because this is observational.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, non-interventional extension collects long-term follow-up data from participants who completed sponsor-initiated cadonilimab (AK104) trials for locally advanced unresectable or metastatic gastric cancer. After giving informed consent, participants' survival status, serious adverse events, subsequent anti-cancer treatments, and other long-term outcomes will be recorded without providing any study treatment. Enrollment is restricted to people who previously received cadonilimab in the original trials and agree to extended follow-up, and concurrent participation in other studies is permitted. Data will be collected at participating sites such as Peking University Cancer Hospital and via routine clinical visits or medical record review.
Why it matters
Potential benefit: If successful, this could clarify the long-term survival and safety profile after cadonilimab and help doctors and patients make more informed treatment decisions.
How similar studies have gone: Long-term observational follow-ups are commonly used for immunotherapies and have yielded useful survival and safety information for similar agents, but cadonilimab-specific long-term data remain limited given its recent approval.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed. 2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial. 3. Agree to proceed with the extended follow-up procedures. 4. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time. Exclusion Criteria: * None
Where it's running
-
Peking University Cancer Hospital
Beijing, China Recruiting
Study contacts
- Principal investigator: Jiafu Ji, MD — Peking University Cancer Hospital & Institute
- Study coordinator: Zhifang Yao，MD
- Email: clinicaltrials@akesobio.com
- Phone: 86-0760-89873999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum
Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.
-
Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer
This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).
-
Cadonilimab with chemotherapy for gastric or GEJ cancer
This trial tests whether adding cadonilimab to standard chemotherapy is safe and effective for adults with locally advanced or resectable gastric or GEJ cancer.
-
Cadonilimab plus high-dose interferon in neoadjuvant treatment for stage III/IV melanoma
This trial tests whether giving cadonilimab with high-dose interferon before surgery can shrink tumors in people with stage III or resectable stage IV melanoma and whether it is safe.
-
LM-302 plus oral S-1 and intraperitoneal paclitaxel, with or without cadonilimab, for Claudin 18.2–positive advanced stomach or GEJ cancer with peritoneal spread
This trial tests whether adding cadonilimab to LM-302, oral S-1, and intraperitoneal paclitaxel helps people with Claudin 18.2–positive gastric or gastroesophageal junction cancer that has spread to the peritoneum.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.